Education
About Us
Working with TipRanks
Follow Us
Harmony Biosciences Holdings (HRMY)
NASDAQ:HRMY
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.63Last Year’s EPS
0.67Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 25, 2025
|% Change Since: 3.22%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in terms of revenue growth and patient base expansion for Harmony Biosciences. Significant advancements in their pipeline, including multiple ongoing and upcoming Phase 3 trials, highlight a solid strategy for future growth. However, the rejection of the Pitolisant sNDA and challenges in clinical trials for idiopathic hypersomnia present notable setbacks. Despite these challenges, the company's financial stability and strategic moves, such as the generic settlement, contribute to an overall positive outlook.Company Guidance
During the Harmony Biosciences Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company provided guidance for 2025, expecting net revenue between $820 million and $860 million, reflecting continued growth from their flagship product, WAKIX. In 2024, WAKIX achieved net product revenues of $714.7 million, marking a 23% growth year-over-year. The company highlighted their success in increasing average patients on WAKIX to approximately 7,100 in Q4, with a significant increase in prescribers. The call also covered strategic pipeline developments, including the initiation of Phase 3 trials for their pitolisant HD formulation in Q4 2025, targeting a PDUFA date in 2028. Harmony plans to expand their leadership in the CNS space by advancing late-stage programs and pursuing pediatric exclusivity for pitolisant, potentially extending its regulatory exclusivity by six months. They also announced a settlement agreement with Novagen Pharma regarding generic competition, reinforcing their strong intellectual property estate.Strong Revenue Growth
Harmony Biosciences reported net product revenues of $714.7 million in 2024, representing a 23% growth year-over-year. Q4 alone generated $201.3 million, reflecting continued growth of WAKIX in narcolepsy.
Expansion of Patient Base
The average number of patients on WAKIX increased to approximately 7,100 in Q4, marking a sequential increase of about 300 patients. This growth was supported by an expanding prescriber base and favorable market access.
Pipeline Advancements
There are four Phase 3 Registrational Trials ongoing, with two more expected to start by the end of the year. These trials cover a range of indications, including narcolepsy, idiopathic hypersomnia, Fragile X Syndrome, and epilepsy.
Financial Stability
Harmony ended 2024 with $576.1 million in cash and cash equivalents, highlighting strong cash generation of approximately $219.8 million from operations in 2024.
Generic Settlement
Harmony announced its first generic settlement agreement with Novagen Pharma, allowing the sale of a generic product beginning January 2030, reinforcing the strength of Harmony's intellectual property.
---
HRMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HRMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 25, 2025 | $34.18 | $36.97 | +8.16% |
| Oct 29, 2024 | $35.75 | $41.49 | +16.06% |
| Aug 06, 2024 | $30.92 | $32.83 | +6.18% |
| Apr 30, 2024 | $29.25 | $30.91 | +5.68% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Harmony Biosciences Holdings (HRMY) report earnings?
Harmony Biosciences Holdings (HRMY) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is Harmony Biosciences Holdings (HRMY) earnings time?
Harmony Biosciences Holdings (HRMY) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HRMY EPS forecast?
HRMY EPS forecast for the fiscal quarter 2025 (Q1) is 0.63.
---